Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hensel

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|April 18, 2003
Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximabManfred Hensel, Anthony D Ho
Seminars in Hematology|March 22, 2006
Pentostatin for the treatment of indolent lymphoproliferative disordersAnthony D Ho, Manfred Hensel
Future Oncology (London, England)|March 28, 2006
Pentostatin and purine analogs for indolent lymphoid malignanciesAnthony D Ho, Manfred Hensel
Oncology Research and Treatment|March 3, 2017
Drug Interactions in the Treatment of Malignancy in HIV-Infected PatientsTanya Welz, Christoph Wyen, Manfred Hensel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
Complementary and alternative medicine in patients with chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Anthony D Ho
Medizinische Klinik (Munich, Germany : 1983)|January 24, 2003
[Stem cell transplantation in primary systemic vasculitis]Manfred Hensel, Christoph Fiehn, Anthony D Ho
BMC Cancer|March 1, 2011
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trialMathias Witzens-Harig, Manfred Hensel, Michael Unterhalt, et al.
Annals of Hematology|July 12, 2007
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximabChristof Schweizer, Frederic J Reu, Anthony D Ho, et al.
British Journal of Haematology|August 6, 2003
Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemiaManfred Hensel, Martin Kornacker, Sophie Yammeni, et al.
Leukemia & Lymphoma|March 23, 2002
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemiaJolanta Perz, Julian Topaly, Stefan Fruehauf, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|April 18, 2003
Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximabManfred Hensel, Anthony D Ho
Seminars in Hematology|March 22, 2006
Pentostatin for the treatment of indolent lymphoproliferative disordersAnthony D Ho, Manfred Hensel
Future Oncology (London, England)|March 28, 2006
Pentostatin and purine analogs for indolent lymphoid malignanciesAnthony D Ho, Manfred Hensel
Oncology Research and Treatment|March 3, 2017
Drug Interactions in the Treatment of Malignancy in HIV-Infected PatientsTanya Welz, Christoph Wyen, Manfred Hensel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
Complementary and alternative medicine in patients with chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Anthony D Ho
Medizinische Klinik (Munich, Germany : 1983)|January 24, 2003
[Stem cell transplantation in primary systemic vasculitis]Manfred Hensel, Christoph Fiehn, Anthony D Ho
BMC Cancer|March 1, 2011
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trialMathias Witzens-Harig, Manfred Hensel, Michael Unterhalt, et al.
Annals of Hematology|July 12, 2007
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximabChristof Schweizer, Frederic J Reu, Anthony D Ho, et al.
British Journal of Haematology|August 6, 2003
Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemiaManfred Hensel, Martin Kornacker, Sophie Yammeni, et al.
Leukemia & Lymphoma|March 23, 2002
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemiaJolanta Perz, Julian Topaly, Stefan Fruehauf, et al.
Pageof 6